Cerebrolysin vs PE 22-28
A side-by-side research comparison of Cerebrolysin and PE 22-28 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | PE 22-28 |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | PE 22-28 (Spadin-Derived TREK-1 Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research peptide (preclinical) |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models. |
| Molecular weight | <10,000 Da (peptide fraction) | ~ (7-residue peptide) |
| Half-life | 4-6 hours | Short (peptide; improved vs spadin) |
| Bioavailability | High (IM/IV) | Intranasal or injection (research) |
| Typical dose | 5-30 mL | Not established for humans |
| Frequency | Daily for 10-20 days | Research only |
| Route | Intramuscular or IV | Intranasal or injection (research) |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
PE 22-28 reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Related comparisons
Research and educational reference only. Not medical advice.